Omega-6 Fatty Acids |
|
|
Clinical Trial: Polyunsaturates and KCL to Control Mild Hypertension
This study has been completed.
Purpose
To test the efficacy of omega-3 fatty acids, magnesium, calcium, and potassium supplementation in untreated mild hypertensives and magnesium and potassium supplementation in treated hypertensives. Three clinical trials were conducted in sequence over a four year period.
| Condition | Treatment or Intervention | Phase |
|---|---|---|
| Cardiovascular Diseases Heart Diseases Hypertension Vascular Diseases | Behavior: diet therapy Drug: fatty acids, omega-3 Behavior: dietary supplements | Phase II |
MedlinePlus related topics: Heart Diseases; Heart Diseases--Prevention; High Blood Pressure; Vascular Diseases
Study Type: Interventional
Study Design: Treatment, Randomized, Crossover Assignment
Study start: December 1983
BACKGROUND: The hypothesis that omega-3 fatty acids as well as magnesium and potassium in the diet lowered blood pressure in mild hypertensives needed further documentation, although preliminary and less well controlled studies had suggested such an effect was possible. In a previous study the investigators did not find a hypotensive effect of another polyunsaturated fatty acid, linoleic acid. In addition, findings of lower blood pressures in vegetarians and results obtained from a study in which vegetarian diets were fed to normotensives led to the conclusion that dietary factors other then linoleic acid were responsible for the possible hypotensive effect of vegetarian diets. The nutrients which were selected for further study, omega-3 fatty acids, magnesium and potassium, occur in higher amounts in vegetarian diets.
Dietary supplementation with fish oils had only been done in a few studies with inconclusive results. However, the relationship of omega-3 fatty acids to the synthesis of prostacyclins, which are locally active vasodilators and which decrease with the excretion of the vasoconstrictor thromboxane, provide a possible mechanism for an effect of these compounds on blood pressure.
The role of potassium in the control of blood pressure was first suggested from cross-cultural studies in which populations consuming high levels of potassium displayed lower rates of hypertension and a decrease in blood pressure with age. Cohort studies within this country have also shown a relationship between potassium intake or the ratio of potassium and sodium, as measured by urinary excretion and blood pressure. Most constantly it found that blood pressure differences between blacks and whites have been related to differences in potassium excretion.
The results from human experimental studies involving potassium supplementation in normotensives and hypertensives have indicated mixed effects but blood pressure lowering was most consistently observed in subgroups with a family history of hypertension or those with higher blood pressure.
DESIGN NARRATIVE: Trial 1: Subjects were randomized to a fish oil treatment group of 6 or 12 grams/day of omega-3 fatty acids or to a placebo group. At the end of 12 and 24 weeks, participants in the three groups were crossed-over to one of the other two treatments for an additional 12 weeks.
Trial 2: Subjects were randomly assigned to one of four treatments: magnesium plus calcium supplementation; potassium plus calcium supplementation; magnesium plus potassium supplementation; matching placebos. The trial was double-blinded. Each of the treatments was administered for six months with measurements taken every three months.
Trial 3: Similar to Trial 2. The primary endpoint in the three trials was change in diastolic blood pressure between baseline and the end of the studies based on an average of nine readings.
Eligibility
Ages Eligible for Study: 21 Years - 70 Years, Genders Eligible for Study: Both
Criteria
More Information
Publications
Morris MC, Taylor JO, Stampfer MJ, Rosner B, Sacks FM. The effect of fish oil on blood pressure in mild hypertensive subjects: a randomized crossover trial. Am J Clin Nutr. 1993 Jan;57(1):59-64.
Record last reviewed: March 2005
Last Updated: March 18, 2005
Record first received: October 27, 1999
ClinicalTrials.gov Identifier: NCT00000511
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08
Source: ClinicalTrials.gov
Cache Date: April 9, 2005

Not Signed In -


